Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Down |
Historical CPRX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Hammer Candlestick | Bullish | 2.10% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 2.10% | |
NR7 | Range Contraction | 2.10% | |
NR7-2 | Range Contraction | 2.10% | |
Fell Below 20 DMA | Bearish | 1.15% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.15% | |
NR7 | Range Contraction | 1.15% | |
NR7-2 | Range Contraction | 1.15% | |
MACD Bearish Signal Line Cross | Bearish | -1.13% | |
20 DMA Support | Bullish | -1.13% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 18 hours ago |
Non-ADX 1,2,3,4 Pullback Entry | about 23 hours ago |
Hammer Candlestick Entry | about 23 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
Up 2% | about 23 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/16/2020
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Industry Health Sciences Medication Virotherapy Disorders Prescription Drug Epilepsy Pharmaceutical Sciences Stage Specialty Pharmaceutical Prescription Drugs Coral Gables Myasthenia Pharmaceutical Partners Urological Diseases Biomarin Pharmaceutical Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Treatment Of Epilepsy
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Industry Health Sciences Medication Virotherapy Disorders Prescription Drug Epilepsy Pharmaceutical Sciences Stage Specialty Pharmaceutical Prescription Drugs Coral Gables Myasthenia Pharmaceutical Partners Urological Diseases Biomarin Pharmaceutical Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Treatment Of Epilepsy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.19 |
52 Week Low | 2.88 |
Average Volume | 1,734,361 |
200-Day Moving Average | 3.78 |
50-Day Moving Average | 4.20 |
20-Day Moving Average | 4.41 |
10-Day Moving Average | 4.45 |
Average True Range | 0.22 |
ADX | 20.31 |
+DI | 24.37 |
-DI | 20.29 |
Chandelier Exit (Long, 3 ATRs ) | 4.38 |
Chandelier Exit (Short, 3 ATRs ) | 4.39 |
Upper Bollinger Band | 4.74 |
Lower Bollinger Band | 4.08 |
Percent B (%b) | 0.46 |
BandWidth | 14.81 |
MACD Line | 0.09 |
MACD Signal Line | 0.12 |
MACD Histogram | -0.0276 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.61 | ||||
Resistance 3 (R3) | 4.60 | 4.50 | 4.57 | ||
Resistance 2 (R2) | 4.50 | 4.44 | 4.51 | 4.56 | |
Resistance 1 (R1) | 4.44 | 4.40 | 4.47 | 4.46 | 4.55 |
Pivot Point | 4.35 | 4.35 | 4.36 | 4.35 | 4.35 |
Support 1 (S1) | 4.29 | 4.29 | 4.32 | 4.30 | 4.21 |
Support 2 (S2) | 4.19 | 4.25 | 4.20 | 4.20 | |
Support 3 (S3) | 4.13 | 4.19 | 4.19 | ||
Support 4 (S4) | 4.15 |